23andMe
next steps | 23andMe
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
30 of 39
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
DICE Therapeutics
Results
March 2023
key from phase efficacy results dice | DICE Therapeutics
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
argenx SE
Results
July 2021
data support favorable benefit to risk ratio four indications clinical proof of concept in no evidence of dose limiting | argenx SE
Other recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Investor Day
January 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights